Yazar "Mirici, Arzu" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Bronş karsinomu ve immünite
    (İnönü Üniversitesi Tıp Fakültesi Dergisi, 1995) Mirici, Arzu; Özbek, Ümit; Kaynar, Hasan; Çildağ, Orhan
    Atatürk Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı kliniğinde bronş karsinomu tanısı konan 30 olguda hücresel ve humoral immüniteyi değerlendirmek amacıyla serum immünglobulin düzeyleri ölçüldü ve tüberkülin cilt testi yapıldı. Sonuçta serum immünglobulin düzeyleri yüksek olmakla birlikte hücre tipi ve evreye göre farklılık göstermezken özellikle ileri evredeki tümörlerde PPD negatijliği daha yüksek oranda saptandı. Bu sonuç akciğer kanserinde evre ile hücresel immünitenin ilişkili olduğunu gösterdi.
  • Küçük Resim Yok
    Öğe
    Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?
    (Lippincott Williams & Wilkins, 2009) Gunen, Hakan; Mirici, Arzu; Meral, Mehmet; Akgun, Metin
    Purpose of review Systemic corticosteroids are strongly recommended in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). As COPD patients are usually elderly and are relatively immobile, side effects of systemic corticosteroids frequently outweigh their beneficial effects. On the contrary, nebulized corticosteroid solutions have a negligible systemic side-effect profile. In this review, as an alternative to systemic corticosteroids, the place of nebulized corticosteroids in exacerbation periods of COPD was summarized. Recent findings The number of trials in the literature is increasing. Regarding the available data, high dose nebulized budesonide was found as effective as systemic corticosteroids in exacerbations of COPD. The side-effect profile, blood glucose level in particular, is better for nebulized budesonide. Summary Findings from recent studies are giving a positive impression on the role of high dose nebulized budesonide in exacerbations of COPD. However, larger and statistically high powered trials testing different types of nebulized corticosteroid solutions with varying dosages are still lacking. Before recommending the routine use of nebulized corticosteroids in exacerbations, present findings need to be confirmed with further studies of high quality.